Topic: inflammatory bowel disease
Genentech signed a $534 million contract with Microbiotica to pan gut bacteria for biomarkers, live bacterial drugs and new targets for IBD.
Armed with $65 million in series A funding, Celsius will sequence defined patient samples to identify the individual cells responsible for disease.
Provention Bio has filed to raise up to $50 million in an IPO, which will bankroll several clinical programs.
The alliance taps into Verily’s work to stratify and analyze white blood cells—and the data abilities come from being part of the same firm as Google.
Topline data show that Arena's ulcerative colitis candidate, etrasimod, beat out placebo in phase 2.
If successful in further trials, OPRX-106 could mount a challenge in the market for injectable and infused TNF drugs.
The funding will propel Finch's lead asset through phase 2 and advance its earlier-stage pipeline.
An oral alternative to injectable anti-TNF drugs—a mainstay of inflammatory disease therapy for decades—has shown encouraging activity in a phase 2 trial.
Scientists at Tufts University have created an “organ on a chip” that could be used to study inflammatory bowel disease and other gut disorders.
Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review.